Life Sciences R&D Credits: The Overlooked Timing Rules That Affect Your Claim

Life sciences companies often experience rapid growth in research expenditures as they move from discovery and preclinical activities into clinical development, manufacturing scale-up and commercialization. As these costs increase, so does the importance of properly accounting for qualified research expenses (QREs) for purposes of the federal and state-level Research & Development (R&D) tax credit.

One area frequently overlooked is the timing of QREs. Specifically, companies must understand how the “when paid or incurred” rule applies to prepaid expenses and accruals. While the issue may seem technical, it can significantly affect the amount and timing of credits claimed and may create audit risk if not applied consistently.

Why Timing Matters for the R&D Credit

Under Internal Revenue Code (IRC) §41, qualified research expenses include wages, supplies, contract research expenses and certain computer usage costs that are paid or incurred during the taxable year in carrying on a trade or business.

For many life sciences companies, research spending often consists of:

Because these arrangements frequently span multiple tax years, determining when a cost becomes a qualified research expense can be just as important as determining whether the expense qualifies in the first place.

How the “When Paid or Incurred” Rule Applies to R&D Tax Credits

The timing of QREs generally follows the taxpayer’s method of accounting. In practice, this means:

Once an accounting method is established for purposes of recognizing qualified research expenses, it should be applied consistently from year to year. Inconsistent treatment can distort credit calculations and attract IRS scrutiny.

For life sciences companies that are rapidly increasing research activity, a consistent methodology is particularly important because fluctuations in clinical spending, contractor utilization and research staffing can already create significant year-over-year changes in credit amounts.

Understanding Prepaid Research Expenses

Prepayments are common throughout the life sciences industry. Companies routinely make advance payments to CROs, contract manufacturers, testing laboratories and software providers before services are performed.

A common misconception is that a prepaid amount automatically qualifies for the R&D credit in the year payment is made. That is often not the case.

The key question is whether the underlying qualified research activity has actually been performed. Simply paying a third party in advance does not, on its own, produce an expense that can be claimed right away.

Example: CRO Prepayment

Assume a biotechnology company pays a CRO $2 million in December 2026 for a Phase I clinical trial expected to begin in February 2027.

Although the cash leaves the company in 2026, the research services will largely be performed in 2027. As noted in the instructions for Form 6765 used to claim the R&D tax credit, prepaid contract research expenses are considered paid in the year the research is actually performed.

Life sciences organizations should carefully evaluate prepaid research arrangements and maintain supporting documentation showing when the underlying research services were performed.

Understanding Accrued Research Expenses

Accrual-basis taxpayers face a different issue.

Many life sciences companies accrue expenses for:

In these situations, the accrual rules determine whether the expense is considered incurred during the year and therefore eligible for inclusion in the R&D credit calculation.

Example: Unbilled Clinical Trial Services

Assume a medical device company receives clinical monitoring services throughout December 2026 but does not receive the invoice until January 2027.

Given that the activities were actually performed during 2026, the expense may be includible as a 2026 QRE even though payment occurs in 2027.

Failure to properly identify these accrued amounts can result in understating the credit, while aggressive treatment of uncertain accruals can create examination risk.

Why Consistent QRE Treatment Matters

One of the most important concepts for life sciences companies is that the treatment of QRE timing should not change from year to year based solely on which approach produces the largest credit.

For example, a company should not:

Once a methodology is established and supported under the taxpayer’s accounting method, it should be applied consistently going forward.

Consistency provides several benefits:

R&D Credit Timing Considerations for Life Sciences Companies

For life sciences companies, the challenge is often not identifying qualified research activities. Discovery research, preclinical development, clinical trials, formulation work, process development and manufacturing scale-up frequently generate substantial eligible expenditures.

The more nuanced issue is determining when those costs should be included in the credit calculation. Prepaid expenses, accruals and contract research arrangements can significantly affect the timing of QREs. Once a taxpayer establishes a supportable method under the “when paid or incurred” framework, that methodology should be applied consistently in future years.

How Withum Can Help

Withum offers a complimentary, no-obligation assessment beginning with a brief 30-minute discussion that can help evaluate your current methodology, assess whether expenses are being recognized consistently and appropriately and identify opportunities to strengthen your credit position. Our team can also assist with calculating, documenting and supporting your R&D tax credits through comprehensive R&D tax credit studies designed to withstand IRS scrutiny and support long-term compliance.